Bionor Pharma’s New Strategy Aiming at a “Functional Cure for HIV”- With Vacc-4x Combination Treatment
(Oslo, Norway, 23 August 2013) Bionor Pharma ASA (OSE: BIONOR) announced today results from the second quarter and first half year of 2013.
Webcast The Q2 report will be presented by webcast 23 August at 8.30 am CEST. Link for registering and access to the webcast: http://www.media-server.com/m/p/gc39czci.
See further information about the webcast and call numbers below.
During the quarter, the Company announced its strategy to combine its therapeutic HIV vaccine candidate Vacc-4x with an HDAC inhibitor (HDACi) in the pursuit of a Functional Cure for HIV. A Functional HIV Cure will enable people to live long-term with no disease progression or HIV transmission in the absence of conventional HIV medication.
The new combination strategy is called "Kick" (HDACi reactivation of virus), "Kill" (Vacc-4x's training of the cellular immune system leading to killing of virus infected cells) and "Boost" (stimulation of the immune system by lenalidomide to enhance the effect of Vacc-4x).
The strategic direction was further reinforced by the presentation of the Danish Professor Lars Østergaard’s preliminary results on HDACi and HIV at the “HIV Cure Symposium” in Kuala Lumpur in June. The trial confirmed the hypothesis that HDACi can reactivate latent HIV in humans.
The Company has made significant progress in planning the Vacc-4x/HDACi Phase I/II study with the clinical research team from University Hospital of Aarhus led by Professor Lars Østergaard, Head of Infectious Diseases.
Discussions with regards to divestment of the nutraceutical business have continued, and exclusive negotiations with interested party are ongoing.
Important milestones were reached in all of the three clinical trials. In the quarter the Company announced the completion of enrollment of both Vacc-4x Reboost Phase II study and Vacc-C5 Phase I/II. In addition, Part A of the Vacc-4x and lenalidomide (Revlimid®) Phase II trial was completed. The trials are progressing according to plan and the Company is able to reconfirm its outlook that results from all clinical trials will be available during H1 of 2014.
Bionor Pharma’s Chief Executive Office Anker Lundemose commented: “After having worked on our new “Kick, Kill and Boost” strategy over the last months, I can only confirm what I said at our Capital Markets Day; if we succeed in executing this in a timely manner I believe that the first mover opportunity that Bionor Pharma has in the HIV space has the potential to drive value creation, partnering and exit optionality going forward”.
The Group reported a net loss of NOK 21.3 million in the second quarter (NOK 14.7 million) and a net loss of NOK 39.6 million (NOK 30.6 million) for the first half 2013. The cash flow from operations in the second quarter was negative NOK 14.3 million (negative NOK 6.8 million) and the net cash position at period end was NOK 74.8 million (NOK 141.9 million).
Webcast with Q&A session
A live audio webcast of the call will be available together with the slide presentation at
http://www.media-server.com/m/p/gc39czci. For the Q&A session at end of the presentation, questions can be written online during the webcast.
For those without a computer available, use the following number: +44(0)20 3427 1919 (UK), +1 646 254 3367 (US), +47 2350 0486 (Norway), +45 32 71 16 58 (Denmark) or +46(0)8 5065 3937 (Sweden), and request to be connected to the Bionor Pharma’s teleconference (confirmation code 2989037). Please use a quiet room.
Schedule for the webcast /teleconference
08.25 -Log in to the webcast-link, and/or call the above number
08.30 -Review of results by Bionor Pharma’s senior management
-Questions and answers
Bionor Pharma ASA
Synne H Røine
Tel + 47 99 22 98 92
About Bionor Pharma ASA
Bionor Pharma is a leading biotechnology company, searching for breakthrough products for the treatment and prevention of life-threatening viral diseases. The Company is listed on the Oslo Stock Exchange, and is developing vaccines for viral infections. The vaccines are based on a proprietary technology platform developed following more than two decades of research into peptides, and they are designed to safely stimulate the immune system to combat viral diseases.
More information about Bionor Pharma is available at www.bionorpharma.com.
This information is subject to the disclosure requirements of §5-12 vphl (Norwegian Securities Trading Act).
Vacc-4x and Vacc-C5 are currently investigational treatments that have not been approved for marketing by any regulatory authority.